publications chronological

2018


Karel P, Almacellas-Barb anoj A, Prijn J, Kaag AM, Reneman L, Verheij MMM,Homberg  JR. 2018. Appetitive to aversive counter-conditioning as intervention to reducereinstatement of reward-seeking behavior: the role of the serotonin transporter. Addict Biol (in press).

van Iersel L, Meijneke RWH, Schouten-van Meeteren AYN, Reneman L, de Win MM, van Trotsenburg ASP, Bisschop PH, Finken MJJ, Vandertop WP, van Furth WR, vanSanten HM. 2018. The development of hypothalamic obesity in craniopharyngioma patients:A risk factor analysis in a well-defined cohort. Pediatr Blood Cancer 65:e26911.

Mugie SM, Koppen IJN, van den Berg MM, Groot PFC, Reneman L, de Ruiter MB,Benninga MA.  2018. Brain processing of rectal sensation in adolescents with functional defecation disorders and healthy controls. Neurogastroenterol Motil (in press).

Karel P, Calabrese F, Riva M, Brivio P, Van der Veen B, Reneman L, Verheij M,  Homberg J. 2018. d-Cycloserine enhanced extinction of cocaine-induced conditioned place preference is attenuated in serotonin transporter knockout rats. Addict Biol. 23:120-129.
2017
Bouziane C, Caan MWA, Tamminga HGH, Schrantee A, Bottelier MA, de  Ruiter MB,Kooij SJJ, Reneman L. 2017. ADHD and maturation of brain white matter: A DTI study inmedication naive children and adults. Neuroimage Clin. 29: 53-59.

Bottelier MA, Schrantee A, Ferguson B, Tamminga HGH, Bouziane C, Kooij JJS, de Ruiter MB, Reneman L. 2017. Age-dependent effects of acute methylphenidate on amygdala  reactivity in stimulant treatment-naive patients with Attention Deficit/Hyperactivity Disorder. Psychiatry Res. 269: 36-42.

Staphorst MS, Benninga MA, Bisschoff M, Bon I, Busschbach JJV, Diederen K, van Goudoever JB, Haarman EG, Hunfeld JAM, Jaddoe VVW, de Jong KJM, de Jongste JC, Kindermann A, Königs M, Oosterlaan J, Passchier J, Pijnenburg MW, Reneman L, Ridder L, Tamminga HG, Tiemeier HW, Timman R, van de Vathorst S. 2017. The child's
perspective on discomfort during medical research procedures: a descriptive study. BMJ Open. 7: e016077.

Schulte MHJ, Kaag AM, Wiers RW, Schmaal L, van den Brink W, Reneman L, Homberg JR, van Wingen GA, Goudriaan AE. 2017. Prefrontal Glx and GABA concentrations and impulsivity in cigarette smokers and smoking polysubstance users. Drug Alcohol Depend. 179:117-123. 

Huffnagel IC, Redeker EJW, Reneman L, Vaz FM, Ferdinandusse S, Poll-The BT. 2017. Mitochondrial Encephalopathy and Transient 3-Methylglutaconic Aciduria in ECHS1 Deficiency: Long-Term Follow-Up. JIMD Rep (in press).  

Solleveld MM, Schrantee A, Puts NAJ, Lucassen PJ, * Reneman L*. 2017. Age-dependent, lasting effects of methylphenidate on the GABAergic system of ADHD patients. Neuroimage Clin. 5: 812-818. *These authors contributed equally 

Schrantee A, Václavů L, Reneman L, Verberne HJ, Booij J, Tan HL. 2017 QT prolongation by dexamphetamine: Does experience matter? J Cardiovasc Electrophysiol. 28: 912-916.


Menning S, de Ruiter MB, Veltman DJ, Boogerd W, Oldenburg HS, Reneman L, Schagen SB. 2017. Changes in brain activation in breast cancer patients depend on cognitive domain and treatment type. PLoS One. 12: e0171724. 

Schrantee A, Tremoleda JL, Wylezinska-Arridge M, Bouet V, Hesseling P, Meerhoff GF, de Bruin KM, Koeleman J, Freret T, Boulouard M, Desfosses E, Galineau L, Gozzi A, Dauphin F, Gsell W, Booij J, Lucassen PJ, Reneman L. 2017.
Repeated dexamphetamine treatment alters the dopaminergic system and increases the phMRI response to methylphenidate. PLoS One 12: e0172776.
 
2016
Schrantee A, Mutsaerts H, Bouziane C, Tamminga H, Bottelier MA, Reneman L. 2016. The age-dependent effects of a single-dose methylphenidate challenge on cerebral perfusion in patients with attention-deficit/hyperactivity disorder. Neuroimage Clin. 13:123-129.

Menning S, de Ruiter MB, Kieffer JM, Agelink van Rentergem J, Veltman DJ, Fruijtier A, Oldenburg HS, Boven E, van der Meij S, Lustig V, Bos ME, Boogerd W, Reneman L, Schagen SB. 2016. Cognitive Impairment in a Subset of Breast Cancer Patients After Systemic Therapy-Results From a Longitudinal Study. J Pain Symptom Manage.  52:560-569.e1

Vegting Y, Reneman L, Booij J. 2016. The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies. Psychopharmacology 233: 3473-3501.

Kaag AM, Schluter RS, Karel P, Homberg J, van den Brink W, Reneman L, van Wingen GA. 2016. Aversive Counterconditioning Attenuates Reward Signaling in the Ventral Striatum. Front Hum Neurosci.10: 418.

Bottelier MA, Schrantee A, van Wingen G, Ruhé HG, de Ruiter MB, Reneman L. 2016. A power analysis for future clinical trials on the potential adverse effects of SSRIs on amygadala reactivity. Front Bio 3: 256-259.

Kaag AM, van Wingen GA, Caan MW, Homberg JR, van den Brink W, Reneman L. 2016. White matter alterations in cocaine users are negatively related to the number of additionally (ab)used substances. Addict Biol 22: 1048-1056.

Schrantee A, Tamminga,HGH, Bouziane C, Bottelier MA, Bron EE, Mutsaerts HJMM, Zwinderman AH, Groote IR, Rombouts SARB, Lindauer RJL, Klein S, Niessen WJ, Opmeer BC, Boer F, Lucassen PJ, Andersen SL, Geurts HM, Reneman L. Age-Dependent Effects of Methylphenidate on the Human Dopaminergic System in Young vs Adult Patients With Attention-Deficit/Hyperactivity Disorder, JAMA Psychiatry 73: 955-962.

van de Vijver I, Ridderinkhof KR, Harsay H, Reneman L, Cavanagh JF, Buitenweg JIV, Cohen MX. Frontostriatal anatomical connections predict reinforcement learning success with increasing task difficulty and age. Neurobiol Aging 46: 1-12.

Tamminga HG, Reneman L, Huizenga HM, Geurts HM. 2016. Effects of methylphenidate on executive functioning in attention-deficit/hyperactivity disorder across the lifespan: a meta-regression analysis. Psychol Med 46:1791-807.

Su T, Wit FW, Caan MW, Schouten J, Prins M, Geurtsen GJ, Cole JH, Sharp DJ, Richard E, Reneman L, Portegies P, Reiss P, Majoie CB; AGEhIV Cohort Study. 2016. White matter hyperintensities in relation to cognition in HIV-infected men with sustained suppressed viral load on cART. AIDS 30: 2329-2339.

Kaag AM, Levar N, Woutersen K, Homberg J, van den Brink W, Reneman L, van Wingen G. 2016. Hyperresponsiveness of the Neural Fear Network During Fear Conditioning and Extinction Learning in Male Cocaine Users. Am J Psychiatry 173: 1033-1042.

van Doorn MMAC, Oude Rengerink K, Newsum EA, Reneman L, Majoie CBLM, Pajkrt E. 2016. Added value of fetal MRI in fetuses with suspected brain abnormalities on neurosonography:  a systematic review and meta-analysis. The Journal of Maternal-Fetal & Neonatal Medicine 29:2949-2961.

Schrantee AGM, Ferguson B, Stoffers D, Booij J, Rombouts SERB, Reneman L. 2016. Effects of dexamphetamine-induced dopamine release on resting-state network connectivity in chronic dexamphetamine users and controls. Brain Imaging and Behavior 10: 548-558.
2015
Tamminga HGH, Reneman L, Huizenga HM, Geurts HM. Effects of methylphenidate on executive functioning in ADHD across the lifespan: A meta-regression analysis. 2015. Psychological Medicine. Journal of Abnormal Child Psychology 46:1791-1807.

van der Marel, Bouet V, Meerhoff G, Freret T, Boulouard M, Dauphin F, Klomp A, Lucassen PJ, Homberg JR, Dijkhuizen RM*, Reneman L*. 2015. Effects of long-term methylphenidate treatment in adolescent and adult rats on hippocampal shape, functional connectivity and adult neurogenesis. Neuroscience 19: 243-258.
*These authors contributed equally 

Stouten-Kemperman M, de Ruiter MB, Caan MWA, Boogerd W, Kerst J, Reneman L, Schagen S. 2015. Lower cognitive performance and white matter changes in testicular cancer survivors 10 years after chemotherapy. Human Brain Mapping 36: 4638-4647.

Crunelle CL, Kaag AM, van den Munkhof HE, Reneman L, Homberg JR, Sabbe B, van den Brink W, van Wingen G. 2015. Dysfunctional amygdala activation and connectivity with the prefrontal cortex in current cocaine users. Hum Brain Mapping 36: 4222-4230.

Reneman L, Schagen SB, Mulder M, Mutsaerts HJ, Hageman G, de Ruiter MB. 2015. Cognitive impairment and associated loss in brain white microstructure in aircrew members exposed to engine oil fumes. Brain Imaging and Behavior 10: 437-444.

Bottelier MA, Schouw MLJ, de Ruiter MB, Ruhe HG, Lindauer RJL, Reneman L. 2015. Effects of methylphenidate during emotional processing in amphetamine users: preliminary findings. Brain Imaging and Behavior 9: 878-886.

Stouten-Kemperman MM, de Ruiter MB, Boogerd W, Veltman DJ, Reneman L, Schagen SB. 2015. Very late treatment-related alterations in brain function of breast cancer survivors. Journal of the International Neuropsychological Society 21: 50-61.

Menning S, de Ruiter MB, Veltman DJ, Kirschbaum C, Boogerd W, Reneman L, Schagen S. 2015. Multimodal MRI and cognitive function in patients with breast cancer prior to adjuvant treatment - The role of fatigue. Neuroimage Clinical 20: 547-554.

Van Schaik SM, Reneman L, Engelen M, Roos YB, Poll-The BT. 2015. Strokelike Episodes and Cutis Marmorata Telangiectatica Congenita. J Child Neurol 30:129-32.

Schrantee A, Vaclavu L, Heijtel DFR, Caan MWA, Gsell W, Lucassen PJ, Nederveen AJ, Booij J, Reneman L. 2015. Dopaminergic system dysfunction in recreational dexamphetamine users. Neuropsychopharmacology 13: 1172-1180

Stouten-Kemperman MM, de Ruiter MB, Koppelmans V, Boogerd W, Reneman L, Schagen SB. 2015. Neurotoxicity in in breast cancer survivors > 10 years post-treatment is dependent on treatment type. Brain Imaging and Behavior 9: 275-284.  
2014
Kaag AM, Crunelle CL, van Wingen G, Homberg J, van den Brink W, Reneman L. 2014. Relationship between trait impulsivity and cortical volume, thickness and surface area in male cocaine users and non-drug using controls. Drug and Alcohol Dependence 144:210-7.

Klomp A, Hamelink R, Feenstra M, Denys D, Reneman L. 2014. Increased Response to a 5-HT Challenge After Discontinuation of Chronic Serotonin Uptake Inhibition in the Adult and Adolescent Rat Brain. PLoS One 17: 9: e99873.

Klomp A, Vaclavu L, Meerhoff GF, Reneman L, Lucassen PJ. 2014. Effects of chronic fluoxetine treatment on neurogenesis and tryptophan hydroxylase expression in adolescent and adult rats. PLoS One 14: 9:e97603.

Schiering IA, de Haan TR, Niermeijer JM, Koelman JH, Majoie CB, Reneman L, Aronica E. 2014. Correlation between clinical and histologic findings in the human neonatal hippocampus after perinatal asphyxia. J Neuropathol Exp Neurol 73:324-34.

Bottelier MA, Schouw ML, Klomp A, Tamminga HG, Schrantee AG, Bouziane C, de Ruiter MB, Boer F, Ruh?� HG, Denys D, Rijsman R, Lindauer RJ, Reitsma HB, Geurts HM, Reneman L. 2014. The effects of Psychotropic drugs On Developing brain (ePOD) study: methods and design. BMC Psychiatry 19;14:48.

Crunelle CL, Kaag AM, van Wingen G, van den Munkhof HE, Homberg JR, Reneman L, van den Brink W. 2014. Reduced frontal brain volume in non-treatment-seekingcocaine-dependent individuals: exploring the role of impulsivity, depression, and smoking. Front Hum Neurosci 17; 8:7.

van der Marel K, Klomp A, Meerhoff GF, Schipper P, Lucassen PJ, Homberg JR, Dijkhuizen RM, Reneman L. 2014. Long-term oral methylphenidate treatment in adolescent  and adult rats: differential effects on brain morphology and function.Neuropsychopharmacology 39:263-73.

Schrantee A, Reneman L. 2014. Pharmacological imaging as a tool to visualize dopaminergic neurotoxicity. Neuropharmacology 84C:159-169.
2013
van Arnhem LA, Bunders MJ, Scherpbier HJ, Majoie CB, Reneman L, Frinking O, Poll-The BT, Kuijpers TW, Pajkrt D. 2013. Neurologic abnormalities in HIV-1 infected children in the era of combination antiretroviral therapy. PLoS One 8:e64398.

Klomp A, van Wingen GA, de Ruiter MB, Caan MW, Denys D, Reneman L. 2013. Test-retest reliability of task-related pharmacological MRI with a single-dose oral citalopram challenge. Neuroimage. 75:108-16.

Schouw ML, Caan MWA, Geurts HM, Schmand B, Booij J, Nederveen AJ, Reneman L. 2013. Monoaminergic dysfunction in recreational users of dexamphetamine. European Neuropsychopharmacology 3:1491-502.

Schouw ML, de Ruiter MB, Kaag AM, van den Brink W, Lindauer RJ, Reneman L. 2013. Dopaminergic dysfunction in abstinent dexamphetamine users: results from a pharmacological fMRI study using a reward anticipation task and a methylphenidate challenge. Drug Alcohol Depend 130:52-60.

Schouw ML, Kaag AM, Caan MW, Heijtel DF, Majoie CB, Nederveen AJ, Booij J, Reneman L. 2013. Mapping the hemodynamic response in human subjects to a dopaminergic challenge with dextroamphetamine using ASL-based pharmacological MRI. Neuroimage 72:1-9.

van Wezel EM, van Santen HM, van Furth WR, Reneman L, Bisschop PH, van Trotsenburg AS. 2012.  [Children with obesity and declining linear growth curve: Cushing's disease. Ned Tijdschr Geneeskd 156:A4677.

Booij, J, Reneman L, Alders M, Kuijpers TW. 2013. Increase in central striatal dopamine transporters in patients with Shwachman-Diamond syndrome: additional evidence of a brain phenotype. Am J Med Genet A 2013;161:102-7. 
2012
Klomp A, Caan MW, Denys D, Nederveen AJ, Reneman L. 2012. Feasibility of ASL-based phMRI with a single dose of oral citalopram for repeated assessment of serotonin  function. Neuroimage 63:1695-700.

Klomp A, den Hollander B, de Bruin CM, Booij J, Reneman L. 2012. The effects of ecstasy (MDMA) on brain serotonin transporters are dependent on age-of-first exposure in  recreational users and animals. Plos One 7:e47524.

den Hollander B, Schouw M, Groot P, Huisman H, Caan M, Barkhof F, Reneman L. 2012. Preliminary evidence of hippocampal damage in chronic users of ecstasy. J Neurol Neurosurg Psychiatry 83:83-5.

Klomp A, Tremoleda JL, Wylezinska M, Nederveen AJ, Feenstra M, Gsell W, Reneman L. 2012. Lasting effects of chronic fluoxetine treatment on the late developing rat brain: age-dependent changes in the serotonergic neurotransmitter system assessed by pharmacological MRI. Neuroimage 59:218-26.

Reneman L, de Win MM, Booij J, van den Brink W, den Heeten GJ, C.B.L.M. Majoie. 2012. Incidental brain findings on MRI in young healthy volunteers: prevalence and clinical implications. AJNR Am  J Neuroradiol. 33:1971-4.

de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, Caan M, Douaud G, Lavini C, Linn SC, Boven E, van Dam FS, Schagen SB. 2012. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: Converging results from multimodal magnetic resonance imaging. Hum Brain Mapp 33:2971-83.

Schouw M, Schagen S,  Caan M, Majoie CBLM, Booij J, Nederveen AJ, Reneman L. 2012. Mapping serotonergic dysfunction in MDMA (ecstasy) users using Pharmacological Magnetic Resonance Imaging. Eur  Neuropsychopharmacol 22:537-45.

Bouet V, Klomp A, Freret T, Wylezinska M, Tremoleda J, Dauphin F, Boulouard M, Jan Booij J, Gsell W, Reneman L. 2012. Chronic fluoxetine treatment affects outgrowth and functionality of the serotonergic system, but not behavior, in an age-dependent manner. Psychopharmacology 221:329-39.

Klomp A, Tremoleda JL, Schrantee A, Gsell W, Reneman L. 2012. The use of pharmacological-challenge fMRI in pre-clinical research: application to the 5-HT system. J Vis Exp. 25. Video link
2011
Harsay HA, Cohen MX, Reneman L, Ridderinkhof KR. 2011. How the aging brain translates motivational incentive into action: the role of individual differences in striato-cortical white matter pathways. Dev Cogn Neurosci 1:530-9.

Homberg JR, Olivier JD, Blom T, Arentsen T, van Brunschot C, Schipper P, Korte-Bouws G, van Luijtelaar G, Reneman L. 2011. Fluoxetine exerts age-dependent effects on behavior and amygdala neuroplasticity in the rat. PLoS One 31: 6, e16646.

de Ruiter MB, Reneman L, Boogerd W, Veltman DJ, van Dam FSAM, Nederveen AJ, Boven E, Schagen S. 2011. Cerebral hyporesponsiveness and cognitive impairment ten years after chemotherapy for breast cancer. Human Brain Mapping 32: 1206-1219.
2009
Aukema EJ, Caan MW, Oudhuis N, Majoie CB, Vos FM, Reneman L, Last BF, Grootenhuis MA, Schouten-van Meeteren AY.  2009. White Matter Fractional Anisotropy Correlates With Speed of Processing and Motor  Speed in Young Childhood Cancer Survivors. Int J Radiat Oncol Biol Phys 74:837-43. 
2008
de Win MM, Jager G, Booij J, Reneman L, Schilt T, Lavini C, Olabarriaga SD, den Heeten GJ, van den Brink W. 2008. Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain 131: 2936-2945.

de Win MM, Jager G, Booij J, Reneman L, Schilt T, Lavini C, Olabarriaga SD, Ramsey NF, Heeten GJ, van den Brink W. 2008. Neurotoxic effects of ecstasy on the thalamus. Br J Psychiatry 193: 289-296.

Visser I, Lavini C, Booij J, Reneman L, Majoie CBLM, de Boer A, Wekking EM, de Joode EA, van der Laan G, van Dijk FJH, Schene AH, den Heeten GJ. 2008. Frontostriatothalamic impairment in chronic solvent-induced encephalopathy. Ann Neurology 63:572-580. 
2007
de Win MML, Reneman L, Jager G, Vlieger EJP, Olabarriaga SD, Lavini C, Bisschops I, Majoie CBLM, Booij J, van den Brink W, den Heeten GJ. 2007. A prospective cohort study on non-acute effects of low dose ecstasy use on the brain in new ecstasy users. Neuropsychopharmacology 32: 458-470. 
2001
Reneman L, Booij J, de Bruin K, de Wolff FA, Gunning WB, den Heeten GJ, vd Brink W. 2001. Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358: 1864-1869.

Reneman L, Booij J, Majoie CBLM, van den Brink W, den Heeten GJ. 2001. The potential neurotoxicity of MDMA: an imaging approach. Hum Psychopharmacol Clin Exp 16: 579-588.

Reneman L, Lavalaye J, Booij J, Schmand B, de Wolff FA, vd Brink W, den Heeten GJ, Booij J. 2001. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethaphetamine (MDMA or "Ecstasy") - Preliminary findings. Arch Gen Psychiatry 58: 901-906.

Reneman L, Majoie CBLM, Schmand B, vd Brink W, den Heeten GJ. 2001. Prefrontal N-acetylaspartate is strongly associated with memory performance in (abstinent) Ecstasy users: Preliminary report. Biol Psychiatry 50: 550-554.

Reneman L, Majoie CBLM, Habraken JBA, den Heeten GJ. 2001. Effects of Ecstasy (MDMA) on the brain in abstinent users: Initial observations with diffusion and perfusion MR imaging. Radiology 220: 611-617.

Reneman L, de Bruin K, Lavalaye J, Gunning WB, Booij J. 2001. Addition of a 5-HT receptor agonist to methylphenidate potentiates the reduction of [123I]FP-CIT binding to dopamine transporters in rat frontal cortex and hippocampus. Synapse 39: 193-200.

Lavalaye J, Sarlet A, Booij J, Linszen DH, Reneman L, Gersons BP, van Royen EA. 2001. Dopamine transporter density in patients with tardive dyskinesia: a single photon emission computed tomography study. Psychopharmacology 155:107-109.

Lavalaye J, Linszen DH, Booij J, Dingemans PM, Reneman L, Habraken JB, Gersons BP, van Royen EA. 2001.  Dopamine transporter density in young patients with schizophrenia assessed with [123I]FP-CIT SPECT. Schizophr Res 47:59-67.

Lavalaye J, Booij J, Linszen DH, Reneman L, van Royen EA. 2001. Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study. Psychopharmacology 156:53-7. 
1999
Reneman L, Booij J, Lavalaye J, de Bruin K, Stoof JC, de Wolff FA, Koopmans RP, den Heeten GJ. 1999. A comparative in vivo study of iodine-123 labelled -CIT and iodine 123 labelled nor--CIT to serotonin transporters in rat brain. Synapse 34: 77-80.

Lavalaye J, Linszen DH, Booij J, Reneman L, Gersons BP, van Royen EA. 1999. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia. Psychiatry Res 92: 33-44.